Moderna returns to oncology
Three off-the-shelf mRNA therapies join intismeran autogene.
Vepdegestrant’s promise narrows
Arvinas and Pfizer abandon first-line atirmociclib combo plans only disclosed in January.
No holding back Claudin
New phase 1 entrants include Claudin18.2-targeting ADCs from Astra and Bolt.
CDH17 becomes flavour of the month
Antibody-drug conjugates hitting this target abound.
FDA red and green lights: April 2025
April saw a checkpoint inhibitor bonanza for Bristol and Akeso.
